This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): Effentora, OraVescent fentanyl, fentanyl effervescent buccal tablet (FEBT)
Description: Fentora uses an effervescent reaction to produce transient shifts in pH levels in the area surrounding the tablet which is thought to enhance the rate and extent of fentanyl absorption through the buccal mucosa. Fentanyl, a pure opioid agonist, acts mainly through interaction with opioid mu-receptors located in the brain, spinal cord and smooth muscle. The primary site of therapeutic action is the central nervous system (CNS). The most clinically useful pharmacologic effects of the interaction of fentanyl with mu-receptors are analgesia and sedation.
Teva no longer reports for Fentora as of Q3 2011.
Fentora was originally developed by Cephalon.
Cephalon and Lundbeck
In February 2011, Lundbeck was granted commercial rights to several Cephalon products in Canada and Latin America. As part of the agreement, Lundbeck will register and commercialise several key products which are currently available in the US and/or Europe on behalf of Cephalon. Key products in the agreement include Fentora (fentanyl buccal tablet), Provigil, Treanda, Trisenox (arsenic trioxide) injection, Myocet (liposomal- doxorubicin) and Nuvigil.
The financial terms of the agreement have not been disclosed, but Lundbeck is to pay double-digit royalties on sales which will be the main overall revenue stream for Cephalon from these products in these territories.
Teva and Cephalon
In May 2011, Teva and Cephalon announced that their Boards of Directors unanimously approved a definitive agreement under which Teva will...See full deal structure in Biomedtracker
Pink Sheet Fentora Expansion Awaits REMS Evaluation
Additional information available to subscribers only: